Wintest
6721
D. Western Therapeutics Institute
4576
Ridge-i
5572
Forside
2330
River Eletec
6666
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -19.87%59.83B | 7.11%81.55B | 13.83%77.58B | 3.90%300.41B | -7.71%81.45B | 6.24%74.67B | 6.35%76.14B | 15.50%68.16B | 28.51%289.14B | 17.27%88.25B |
Cost of revenue | -23.80%17.28B | 13.48%25.04B | 12.73%21.47B | 6.68%89.21B | 7.06%25.42B | 8.14%22.68B | 6.39%22.06B | 4.84%19.05B | 22.83%83.62B | 15.22%23.74B |
Gross profit | -18.16%42.55B | 4.51%56.51B | 14.26%56.11B | 2.76%211.2B | -13.15%56.02B | 5.42%51.99B | 6.33%54.07B | 20.24%49.11B | 30.98%205.52B | 18.04%64.5B |
Operating expense | -13.18%40.27B | 2.39%50.67B | 11.40%48.2B | 6.44%195.21B | 2.19%56.07B | 5.31%46.38B | 12.43%49.49B | 6.93%43.27B | 32.84%183.39B | 4.52%54.87B |
Staff costs | -10.29%13.26B | 2.28%15.47B | 8.30%15.37B | 5.14%60.2B | 7.70%16.1B | 5.19%14.79B | 6.94%15.13B | 0.57%14.19B | 27.57%57.26B | 8.72%14.95B |
Selling and administrative expenses | -8.47%19.54B | -1.82%23.74B | 11.53%21.76B | 6.30%92.86B | -3.28%27.82B | 7.03%21.35B | 17.53%24.18B | 7.99%19.51B | 33.52%87.35B | -1.89%28.77B |
-Selling and marketing expense | -10.74%14.99B | -3.58%18.96B | 17.07%17.2B | 5.86%74.04B | -3.04%22.89B | 8.16%16.8B | 18.98%19.66B | 2.90%14.69B | 33.90%69.93B | -5.65%23.6B |
-General and administrative expense | -0.11%4.55B | 5.85%4.78B | -5.38%4.56B | 8.07%18.82B | -4.41%4.94B | 3.03%4.55B | 11.62%4.51B | 27.20%4.82B | 32.02%17.41B | 19.98%5.17B |
Depreciation and amortization | 1.10%1.28B | -14.42%1.26B | 18.84%1.25B | 2.99%5.06B | 3.92%1.27B | -11.01%1.27B | 10.11%1.47B | 13.01%1.05B | 29.61%4.92B | 0.00%1.23B |
-Depreciation | 1.10%1.28B | -14.42%1.26B | 18.84%1.25B | 2.99%5.06B | 3.92%1.27B | -11.01%1.27B | 10.11%1.47B | 13.01%1.05B | 29.61%4.92B | 0.00%1.23B |
Other operating expenses | -31.15%6.18B | 17.07%10.21B | 15.34%9.83B | 9.51%37.09B | 9.56%10.87B | 4.21%8.98B | 9.41%8.72B | 15.74%8.52B | 41.39%33.87B | 21.05%9.93B |
Operating profit | -59.32%2.28B | 27.43%5.84B | 35.44%7.91B | -27.73%15.99B | -100.46%-44M | 6.39%5.61B | -32.93%4.59B | 1,456.80%5.84B | 17.33%22.12B | 347.91%9.64B |
Net non-operating interest income (expenses) | 73.33%390M | -15.27%233M | -33.06%249M | 116.15%1.12B | 4.13%252M | 5.63%225M | 409.26%275M | 3,281.82%372M | 263.64%520M | 365.38%242M |
Non-operating interest income | 74.22%392M | -11.15%239M | -35.40%250M | 95.69%1.14B | -12.11%254M | 14.21%225M | 371.93%269M | 945.95%387M | 274.19%580M | 407.02%289M |
Non-operating interest expense | --2M | 200.00%6M | -93.33%1M | -81.67%11M | -95.74%2M | --0 | -300.00%-6M | -42.31%15M | 400.00%60M | 840.00%47M |
Net investment income | -180.79%-753M | -5.06%2.21B | 767.23%2.04B | -51.37%2.2B | 68.51%-1.3B | -49.10%932M | -45.87%2.33B | -90.65%235M | 183.97%4.52B | -238.66%-4.13B |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -361.54%-102M | 421.74%74M | 313.33%32M | 100.61%1M | 0 | 160.94%39M | 67.14%-23M | 11.76%-15M | -125.95%-164M | 23.53%-13M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | -362.34%-356M | -73.63%-158M | 86.72%-53M | -47.24%-854M | -64.00%-287M | 42.11%-77M | 28.91%-91M | -177.08%-399M | 51.22%-580M | 18.98%-175M |
Less:Other special charges | 313.11%252M | 437.14%188M | -97.73%8M | 81.91%553M | 8.25%105M | -1.61%61M | -35.19%35M | 286.81%352M | -67.45%304M | 267.24%97M |
Less:Write off | 550.00%104M | -153.57%-30M | -4.26%45M | 9.06%301M | 133.33%182M | -77.46%16M | -24.32%56M | -11.32%47M | 8.24%276M | --78M |
Other non-operating income (expenses) | 102.29%441M | -22.18%200M | -61.03%106M | -27.72%1.05B | 133.85%304M | 59.12%218M | -75.19%257M | 80.13%272M | 11.33%1.45B | -44.92%130M |
Income before tax | -72.71%1.9B | 14.56%8.41B | 63.22%10.27B | -30.00%19.51B | -118.85%-1.07B | -4.29%6.94B | -39.00%7.34B | 118.16%6.29B | 30.62%27.87B | 9.71%5.69B |
Income tax | -83.41%361M | 42.61%3.33B | 35.37%3.14B | -16.93%6.97B | -74.91%144M | 1.26%2.18B | -45.79%2.33B | 69.66%2.32B | 9.98%8.4B | -72.23%574M |
Net income | -67.82%1.53B | 1.48%5.08B | 79.53%7.13B | -35.65%12.53B | -123.78%-1.22B | -6.64%4.77B | -35.22%5.01B | 162.01%3.97B | 42.11%19.47B | 63.93%5.12B |
Net income continuous operations | -67.82%1.53B | 1.50%5.08B | 79.49%7.13B | -35.64%12.53B | -123.78%-1.22B | -6.62%4.77B | -35.22%5.01B | 161.90%3.97B | 42.11%19.47B | 63.99%5.12B |
Noncontrolling interests | -101.26%-4M | 100.00%416M | 150.67%188M | 24.00%868M | 43.32%268M | 112.75%317M | -27.02%208M | -5.06%75M | 94.44%700M | 202.75%187M |
Net income attributable to the company | -65.45%1.54B | -2.77%4.67B | 78.16%6.94B | -37.87%11.66B | -130.12%-1.49B | -10.23%4.45B | -35.54%4.8B | 171.19%3.9B | 40.70%18.77B | 49.17%4.93B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -65.45%1.54B | -2.77%4.67B | 78.16%6.94B | -37.87%11.66B | -130.12%-1.49B | -10.23%4.45B | -35.54%4.8B | 171.19%3.9B | 40.70%18.77B | 49.17%4.93B |
Gross dividend payment | ||||||||||
Basic earnings per share | -65.45%26.9518 | -2.79%81.78 | 78.12%121.69 | -37.87%204.43 | -130.11%-26.02 | -10.23%78 | -35.54%84.13 | 171.11%68.32 | 40.70%329.03 | 49.18%86.42 |
Diluted earnings per share | -65.45%26.9518 | -2.79%81.78 | 78.12%121.69 | -37.87%204.43 | -130.12%-26.0264 | -10.23%78 | -35.54%84.13 | 171.11%68.32 | 40.70%329.03 | 49.16%86.4085 |
Dividend per share | 0 | 0.00%70 | 0 | 0.00%140 | 0.00%70 | 0 | 0.00%70 | 0 | 140 | 16.67%70 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |